This trial is unknown!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Carcinoma, Non-Small-Cell Lung
and you are
between 20 and 79
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

The investigators identified three cancer-testis antigens, as targets for cancer vaccination against lung cancer. In this clinical study, the investigators examine using a combination of three peptides from these three antigens (S-488410) the safety, immunogenicity, and antitumor effect of vaccine treatment for advanced non-small cell lung cancer patients.

Provided treatments

  • Drug: S-488410

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01592617. The sponsor of the trial is Shiga University and it is looking for 45 volunteers for the current phase.
Official trial title:
Phase II Study of Peptide Cancer Vaccine S-488410 to Treat Advanced Non-Small Cell Lung Cancer